ClinicalTrials.gg
CompletedNCT04436107Updated May 23, 2025Results posted

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 1 interventional study of Zanubrutinib and Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, sponsored by BeiGene. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse — 19 open to participants now, 23 under way, 1 of them phase 3. zanubrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
6th of 30
66 · median 39
Started
2020
with 2 others
Phase 1
3 of 30
1 open now
Registered
3rd of 30
by date
Lead sponsor
4 of 30
BeiGene

Among the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by enrollment, is one of 3 that started in 2020, is one of 3 in phase 1, and was the 3rd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

19 of the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed DLBCL, all participants must provide sufficient archival or fresh tumor tissue samples for evaluation by immunohistochemistry (IHC) and Gene Expression Profiling (GEP).
  2. disease, defined as either: 1) progression of disease after having achieved disease remission (complete response [CR] or partial response [PR]) , or 2) stable disease (SD), or progressive disease (PD) at completion of the treatment regimen preceding entry to the study.
  3. Participants who have not received high dose therapy/stem cell transplantation (HDT/SCT) must be ineligible for HDT/SCT.
  4. as defined by at least 1 lymph node >1.5 cm in longest diameter, or at least 1 extra-nodal lesion >1.0 cm in longest diameter, and measurable in 2 perpendicular dimensions.
  5. Received an appropriate therapy for DLBCL,defined as an anti CD20 antibody and an appropriate anthracycline-based combination therapy for at least 2 cycles, unless the patient is intolerant or had disease progression before Cycle 2..

Key Exclusion Criteria:

  1. Current or history of central nervous system (CNS) lymphoma.
  2. Histologically transformed lymphoma.
  3. History of stem-cell transplantation.
  4. Prior exposure to a BTK inhibitor.
  5. Prior exposure to lenalidomide or thalidomide.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Part 1: Zanubrutinib + Lenalidomide 15 mg

    Participants received zanubrutinib 160 mg orally twice a day (BID) and lenalidomide 15 mg orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.

    Drug: Zanubrutinib · Drug: Lenalidomide

  • Experimental
    Part 1: Zanubrutinib + Lenalidomide 20 mg

    Participants received zanubrutinib 160 mg orally BID and lenalidomide 20 mg orally QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.

    Drug: Zanubrutinib · Drug: Lenalidomide

  • Experimental
    Part 1: Zanubrutinib + Lenalidomide 25 mg

    Participants received zanubrutinib 160 mg orally BID and lenalidomide 25 mg orally QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.

    Drug: Zanubrutinib · Drug: Lenalidomide

  • Experimental
    Part 2: Zanubrutinib + Lenalidomide 25 mg

    Participants received zanubrutinib 160 mg orally BID and lenalidomide 25 mg orally QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.

    Drug: Zanubrutinib · Drug: Lenalidomide

Interventions

  • 160 mg administered orally twice daily (BID)

    Also known as: BGB-3111, BRUKINSA

  • Administered orally on Days 1-21 each cycle followed by a mandatory 7-day drug-free interval.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).

    Time frame: From first dose of study drug to 30 days after last dose. Maximum time on treatment in Part 1 was 1260 days.

  2. Part 2: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDG-PET)). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.

Secondary outcomes

  1. Part 1: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved a best overall response of partial response or complete response based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.

  2. Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  3. Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  4. Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Zanubrutinib After a Single Dose

    Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1, 0.5, 1, 2, 3, 4, and 8 hours postdose

  5. Maximum Plasma Concentration (Cmax) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  6. Time to Maximum Plasma Concentration (Tmax) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  7. Time to the Last Quantifiable Concentration (Tlast) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  8. Apparent Terminal Elimination Half-life (T1/2) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  9. Apparent Volume (CL/F) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  10. Apparent Clearance (Vz/F) of Zanubrutinib After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  11. Accumulation Ratio of AUCt for Zanubrutinib

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to the AUCt after the first dose (Day 1).

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  12. Accumulation Ratio of Cmax for Zanubrutinib

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to the Cmax after the first dose (Day 1).

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  13. Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  14. AUClast of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  15. AUCinf of Lenalidomide After a Single Dose

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  16. Cmax of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  17. Tmax of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  18. Tlast of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  19. T1/2 of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  20. CL/F of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  21. Vz/F of Lenalidomide After a Single Dose and at Steady State

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  22. Accumulation Ratio of AUCt for Lenalidomide

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to AUCt after the first dose (Day 1).

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  23. Accumulation Ratio of Cmax for Lenalidomide

    Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to Cmax after the first dose (Day 1).

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose

  24. Part 1: Overall Response Rate by Immunohistochemistry Subtypes

    ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry (IHC) was used to identify germinal B-cell-like (GCB) and non-GCB phenotypes.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.

  25. Part 1: Overall Response Rate by Gene Expression Profiling (GEP) Subtypes

    The percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin (COO) assay was used to determine activated B-cell like (ABC) and GCB subtypes.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.

  26. Part 2: Overall Response Rate by Immunohistochemistry Subtypes

    ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.

  27. Part 2: Overall Response Rate by Gene Expression Profiling Subtypes

    ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL COO assay was used to determine ABC and GCB subtypes.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.

  28. Part 2: Complete Response Rate (CRR)

    CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline).

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.

  29. Part 2: Complete Response Rate by Immunohistochemistry Subtypes

    CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.

  30. Part 2: Complete Response Rate by Gene Expression Profiling Subtypes

    CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.

  31. Part 2: Duration of Response (DOR)

    DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. PD: Progressive metabolic disease (increased FDG uptake from Baseline and/or new FDG-avid foci consistent with lymphoma), abnormal node or lesions with longest diameter \> 1.5 cm, an increase of ≥ 50% in the product of the perpendicular diameters, and an increase in the longest diameter of 0.5 cm for lesions ≤ 2 cm or 1.0 cm for lesions \> 2 cm, or any new lesions.

    Time frame: From first dose to the end of study; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.

  32. Part 2: Duration of Response by Immunohistochemistry Subtypes

    DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

    Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.

  33. Part 2: Duration of Response by Gene Expression Profiling Subtypes

    DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

    Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.

  34. Part 2: Progression-free Survival (PFS)

    PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment.

    Time frame: From first dose to the end of study; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.

  35. Part 2: Progression-Free Survival by Immunohistochemistry Subtypes

    PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

    Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.

  36. Part 2: Progression-Free Survival by Gene Expression Profiling Subtypes

    PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

    Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.

  37. Part 2: Time to Response (TTR)

    Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.

  38. Part 2: Time to Response by Immunohistochemistry Subtypes

    Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

    Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.

  39. Part 2: Time to Response by Gene Expression Profiling Subtypes

    Time to response is defined as the time from the starting date of combination therapy to the date objective response criteria were first met. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

    Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.

  40. Part 2: Number of Participants With Treatment-emergent Adverse Events

    An AE is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).

    Time frame: From first dose of study drug to 30 days after last dose. Maximum time on treatment in Part 2 was 701 days.

07

Results

Posted May 23, 2025

Participant flow

This study was conducted at 10 study centers in China. Participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) ineligible for high-dose therapy/stem cell transplant who had received ≥ 1 prior line of systemic therapy were enrolled.

Participant flow — Overall Study
MilestonePart 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mgPart 2: Zanubrutinib + Lenalidomide 25 mg
Started6101139
Completed0000
Not completed6101139
Withdrew: Sponsor ended study24820
Withdrew: Death35318
Withdrew: Withdrawal by subject1101

Outcome measures

PrimaryPart 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).

Time frame:
From first dose of study drug to 30 days after last dose. Maximum time on treatment in Part 1 was 1260 days.
Reported as:
Count of participants · Participants
Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
ParticipantsPart 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mg
TEAEs61011
SAEs034
PrimaryPart 2: Overall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDG-PET)). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Reported as:
Number · percentage of participants
Part 2: Overall Response Rate (ORR)
percentage of participantsPart 2: Zanubrutinib + Lenalidomide 25 mgPart 1+2: Zanubrutinib + Lenalidomide 25 mg
Part 2: Overall Response Rate (ORR)48.7 (32.4 to 65.2)58.0 (43.2 to 71.8)
SecondaryPart 1: Overall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved a best overall response of partial response or complete response based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.
Reported as:
Number · percentage of participants
Part 1: Overall Response Rate (ORR)
percentage of participantsPart 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mg
Part 1: Overall Response Rate (ORR)16.7 (0.4 to 64.1)30.0 (6.7 to 65.2)90.9 (58.7 to 99.8)
SecondaryArea Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Zanubrutinib After a Single Dose and at Steady State
h*ng/mLDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Zanubrutinib After a Single Dose and at Steady State847.8 ± 80623.9 ± 49
SecondaryArea Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Zanubrutinib After a Single Dose and at Steady State
h*ng/mLDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Zanubrutinib After a Single Dose and at Steady State798.4 ± 94638.4 ± 57
SecondaryArea Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Zanubrutinib After a Single Dose

Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1, 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Zanubrutinib After a Single Dose
h*ng/mLDay 1 Zanubrutinib + Lenalidomide
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Zanubrutinib After a Single Dose943.3 ± 81
SecondaryMaximum Plasma Concentration (Cmax) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Zanubrutinib After a Single Dose and at Steady State
ng/mLDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Maximum Plasma Concentration (Cmax) of Zanubrutinib After a Single Dose and at Steady State281.2 ± 85208.7 ± 61
SecondaryTime to Maximum Plasma Concentration (Tmax) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Zanubrutinib After a Single Dose and at Steady State
hoursDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Time to Maximum Plasma Concentration (Tmax) of Zanubrutinib After a Single Dose and at Steady State2.0 (0.9 to 8.0)2.5 (0.4 to 8.0)
SecondaryTime to the Last Quantifiable Concentration (Tlast) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Median · hours
Time to the Last Quantifiable Concentration (Tlast) of Zanubrutinib After a Single Dose and at Steady State
hoursDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Time to the Last Quantifiable Concentration (Tlast) of Zanubrutinib After a Single Dose and at Steady State7.9 (7.5 to 8.2)7.9 (7.5 to 8.1)
SecondaryApparent Terminal Elimination Half-life (T1/2) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · hours
Apparent Terminal Elimination Half-life (T1/2) of Zanubrutinib After a Single Dose and at Steady State
hoursDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Apparent Terminal Elimination Half-life (T1/2) of Zanubrutinib After a Single Dose and at Steady State1.4 (0.9 to 3.1)1.6 (1.1 to 3.0)
SecondaryApparent Volume (CL/F) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · L/h
Apparent Volume (CL/F) of Zanubrutinib After a Single Dose and at Steady State
L/hDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Apparent Volume (CL/F) of Zanubrutinib After a Single Dose and at Steady State165.9 ± 80226.5 ± 46
SecondaryApparent Clearance (Vz/F) of Zanubrutinib After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · liters
Apparent Clearance (Vz/F) of Zanubrutinib After a Single Dose and at Steady State
litersDay 1 Zanubrutinib + LenalidomideDay 21 Zanubrutinib + Lenalidomide
Apparent Clearance (Vz/F) of Zanubrutinib After a Single Dose and at Steady State341.4 ± 69533.8 ± 54
SecondaryAccumulation Ratio of AUCt for Zanubrutinib

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to the AUCt after the first dose (Day 1).

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · ratio
Accumulation Ratio of AUCt for Zanubrutinib
ratioZanubrutinib + Lenalidomide
Accumulation Ratio of AUCt for Zanubrutinib0.7 ± 50
SecondaryAccumulation Ratio of Cmax for Zanubrutinib

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to the Cmax after the first dose (Day 1).

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · ratio
Accumulation Ratio of Cmax for Zanubrutinib
ratioZanubrutinib + Lenalidomide
Accumulation Ratio of Cmax for Zanubrutinib0.8 ± 73
SecondaryArea Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Lenalidomide After a Single Dose and at Steady State
h*ng/mLDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Lenalidomide After a Single Dose and at Steady State843.5 ± 511092.5 ± 591177.7 ± 1251091.0 ± 34916.1 ± 391702.6 ± 29
SecondaryAUClast of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · h*ng/mL
AUClast of Lenalidomide After a Single Dose and at Steady State
h*ng/mLDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
AUClast of Lenalidomide After a Single Dose and at Steady State641.9 ± 911072.7 ± 561187.4 ± 112778.7 ± 69824.6 ± 411389.7 ± 53
SecondaryAUCinf of Lenalidomide After a Single Dose

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · h*ng/mL
AUCinf of Lenalidomide After a Single Dose
h*ng/mLDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mg
AUCinf of Lenalidomide After a Single Dose933.7 ± 521443.2 ± 291752.4 ± 28
SecondaryCmax of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · ng/mL
Cmax of Lenalidomide After a Single Dose and at Steady State
ng/mLDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
Cmax of Lenalidomide After a Single Dose and at Steady State206.4 ± 118276.5 ± 68332.0 ± 123238.5 ± 132206.6 ± 57372.1 ± 67
SecondaryTmax of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Median · hours
Tmax of Lenalidomide After a Single Dose and at Steady State
hoursDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
Tmax of Lenalidomide After a Single Dose and at Steady State1.5 (0.5 to 7.6)1.5 (0.9 to 4.3)2.0 (0.5 to 4.1)1.9 (0.5 to 3.8)2.1 (0.6 to 4.0)1.9 (0.4 to 7.9)
SecondaryTlast of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Median · hours
Tlast of Lenalidomide After a Single Dose and at Steady State
hoursDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
Tlast of Lenalidomide After a Single Dose and at Steady State7.6 (7.6 to 8.0)7.9 (7.6 to 8.2)8.0 (7.5 to 8.1)7.7 (7.5 to 7.9)7.7 (7.5 to 8.1)8.0 (7.5 to 8.1)
SecondaryT1/2 of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · hours
T1/2 of Lenalidomide After a Single Dose and at Steady State
hoursDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
T1/2 of Lenalidomide After a Single Dose and at Steady State2.3 (2.0 to 2.6)2.7 (1.7 to 3.9)2.5 (1.7 to 7.7)2.0 (1.8 to 2.2)2.3 (2.0 to 2.9)2.4 (1.9 to 3.4)
SecondaryCL/F of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · L/h
CL/F of Lenalidomide After a Single Dose and at Steady State
L/hDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
CL/F of Lenalidomide After a Single Dose and at Steady State16.1 ± 5216.0 ± 5213.9 ± 4112.8 ± 3517.6 ± 3612.5 ± 31
SecondaryVz/F of Lenalidomide After a Single Dose and at Steady State

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · liters
Vz/F of Lenalidomide After a Single Dose and at Steady State
litersDay 1 Zanubrutinib + Lenalidomide 15 mgDay 1 Zanubrutinib + Lenalidomide 20 mgDay 1 Zanubrutinib + Lenalidomide 25 mgDay 21 Zanubrutinib + Lenalidomide 15 mgDay 21 Zanubrutinib + Lenalidomide 20 mgDay 21 Zanubrutinib + Lenalidomide 25 mg
Vz/F of Lenalidomide After a Single Dose and at Steady State53.6 ± 4262.1 ± 7649.7 ± 4937.3 ± 1957.6 ± 2843.6 ± 20
SecondaryAccumulation Ratio of AUCt for Lenalidomide

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to AUCt after the first dose (Day 1).

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · ratio
Accumulation Ratio of AUCt for Lenalidomide
ratioZanubrutinib + Lenalidomide 15 mgZanubrutinib + Lenalidomide 20 mgZanubrutinib + Lenalidomide 25 mg
Accumulation Ratio of AUCt for Lenalidomide1.1 ± 480.8 ± 1061.0 ± 27
SecondaryAccumulation Ratio of Cmax for Lenalidomide

Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to Cmax after the first dose (Day 1).

Time frame:
Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Reported as:
Geometric mean · ratio
Accumulation Ratio of Cmax for Lenalidomide
ratioZanubrutinib + Lenalidomide 15 mgZanubrutinib + Lenalidomide 20 mgZanubrutinib + Lenalidomide 25 mg
Accumulation Ratio of Cmax for Lenalidomide1.3 ± 510.8 ± 1000.9 ± 59
SecondaryPart 1: Overall Response Rate by Immunohistochemistry Subtypes

ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry (IHC) was used to identify germinal B-cell-like (GCB) and non-GCB phenotypes.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.
Reported as:
Number · percentage of participants
Part 1: Overall Response Rate by Immunohistochemistry Subtypes
percentage of participantsGCB Subtype: Zanubrutinib + Lenalidomide 15 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 15 mgGCB Subtype: Zanubrutinib + Lenalidomide 20 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 20 mgGCB Subtype: Zanubrutinib + Lenalidomide 25 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 1: Overall Response Rate by Immunohistochemistry Subtypes33.3 (0.8 to 90.6)0.0 (0.0 to 70.8)50.0 (6.8 to 93.2)16.7 (0.4 to 64.1)66.7 (9.4 to 99.2)100.0 (63.1 to 100.0)
SecondaryPart 1: Overall Response Rate by Gene Expression Profiling (GEP) Subtypes

The percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin (COO) assay was used to determine activated B-cell like (ABC) and GCB subtypes.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.
Reported as:
Number · percentage of participants
Part 1: Overall Response Rate by Gene Expression Profiling (GEP) Subtypes
percentage of participantsABC Subtype: Zanubrutinib + Lenalidomide 15 mgGCB Subtype: Zanubrutinib + Lenalidomide 15 mgABC Subtype: Zanubrutinib + Lenalidomide 20 mgGCB Subtype: Zanubrutinib + Lenalidomide 20 mgABC Subtype: Zanubrutinib + Lenalidomide 25 mgGCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 1: Overall Response Rate by Gene Expression Profiling (GEP) Subtypes0.0 (0.0 to 97.5)0.0 (0.0 to 97.5)12.5 (0.3 to 52.7)100.0 (15.8 to 100.0)88.9 (51.8 to 99.7)100.0 (15.8 to 100.0)
SecondaryPart 2: Overall Response Rate by Immunohistochemistry Subtypes

ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Number · percentage of participants
Part 2: Overall Response Rate by Immunohistochemistry Subtypes
percentage of participantsGCB Subtype: Zanubrutinib + Lenalidomide 25 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Overall Response Rate by Immunohistochemistry Subtypes50.0 (24.7 to 75.3)61.8 (43.6 to 77.8)
SecondaryPart 2: Overall Response Rate by Gene Expression Profiling Subtypes

ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL COO assay was used to determine ABC and GCB subtypes.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Number · percentage of participants
Part 2: Overall Response Rate by Gene Expression Profiling Subtypes
percentage of participantsABC Subtype: Zanubrutinib + Lenalidomide 25 mgGCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Overall Response Rate by Gene Expression Profiling Subtypes68.6 (50.7 to 83.1)45.5 (16.7 to 76.6)
SecondaryPart 2: Complete Response Rate (CRR)

CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline).

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Reported as:
Number · percentage of participants
Part 2: Complete Response Rate (CRR)
percentage of participantsPart 2: Zanubrutinib + Lenalidomide 25 mgPart 1+2: Zanubrutinib + Lenalidomide 25 mg
Part 2: Complete Response Rate (CRR)33.3 (19.1 to 50.2)42.0 (28.2 to 56.8)
SecondaryPart 2: Complete Response Rate by Immunohistochemistry Subtypes

CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Number · percentage of participants
Part 2: Complete Response Rate by Immunohistochemistry Subtypes
percentage of participantsGCB Subtype: Zanubrutinib + Lenalidomide 25 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Complete Response Rate by Immunohistochemistry Subtypes50.0 (24.7 to 75.3)38.2 (22.2 to 56.4)
SecondaryPart 2: Complete Response Rate by Gene Expression Profiling Subtypes

CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Number · percentage of participants
Part 2: Complete Response Rate by Gene Expression Profiling Subtypes
percentage of participantsABC Subtype: Zanubrutinib + Lenalidomide 25 mgGCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Complete Response Rate by Gene Expression Profiling Subtypes45.7 (28.8 to 63.4)45.5 (16.7 to 76.6)
SecondaryPart 2: Duration of Response (DOR)

DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. PD: Progressive metabolic disease (increased FDG uptake from Baseline and/or new FDG-avid foci consistent with lymphoma), abnormal node or lesions with longest diameter \> 1.5 cm, an increase of ≥ 50% in the product of the perpendicular diameters, and an increase in the longest diameter of 0.5 cm for lesions ≤ 2 cm or 1.0 cm for lesions \> 2 cm, or any new lesions.

Time frame:
From first dose to the end of study; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Duration of Response (DOR)
monthsPart 2: Zanubrutinib + Lenalidomide 25 mgPart 1+2: Zanubrutinib + Lenalidomide 25 mg
Part 2: Duration of Response (DOR)9.10 (2.79 to NA)14.92 (5.45 to NA)
SecondaryPart 2: Duration of Response by Immunohistochemistry Subtypes

DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

Time frame:
From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Duration of Response by Immunohistochemistry Subtypes
monthsGCB Subtype: Zanubrutinib + Lenalidomide 25 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Duration of Response by Immunohistochemistry SubtypesNA (2.76 to NA)11.61 (2.83 to NA)
SecondaryPart 2: Duration of Response by Gene Expression Profiling Subtypes

DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

Time frame:
From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Duration of Response by Gene Expression Profiling Subtypes
monthsABC Subtype: Zanubrutinib + Lenalidomide 25 mgGCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Duration of Response by Gene Expression Profiling Subtypes15.67 (3.02 to NA)9.10 (3.02 to NA)
SecondaryPart 2: Progression-free Survival (PFS)

PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment.

Time frame:
From first dose to the end of study; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Progression-free Survival (PFS)
monthsPart 2: Zanubrutinib + Lenalidomide 25 mgPart 1+2: Zanubrutinib + Lenalidomide 25 mg
Part 2: Progression-free Survival (PFS)4.76 (2.73 to 8.94)5.52 (2.86 to 11.07)
SecondaryPart 2: Progression-Free Survival by Immunohistochemistry Subtypes

PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

Time frame:
From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Progression-Free Survival by Immunohistochemistry Subtypes
monthsGCB Subtype: Zanubrutinib + Lenalidomide 25 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Progression-Free Survival by Immunohistochemistry Subtypes5.55 (1.61 to NA)5.52 (2.86 to 11.04)
SecondaryPart 2: Progression-Free Survival by Gene Expression Profiling Subtypes

PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

Time frame:
From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Progression-Free Survival by Gene Expression Profiling Subtypes
monthsABC Subtype: Zanubrutinib + Lenalidomide 25 mgGCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Progression-Free Survival by Gene Expression Profiling Subtypes5.55 (4.76 to 18.40)5.40 (1.41 to 14.65)
SecondaryPart 2: Time to Response (TTR)

Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Time to Response (TTR)
monthsPart 2: Zanubrutinib + Lenalidomide 25 mgPart 1+2: Zanubrutinib + Lenalidomide 25 mg
Part 2: Time to Response (TTR)2.76 (2.73 to 2.89)2.76 (2.73 to 2.83)
SecondaryPart 2: Time to Response by Immunohistochemistry Subtypes

Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.

Time frame:
Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Time to Response by Immunohistochemistry Subtypes
monthsGCB Subtype: Zanubrutinib + Lenalidomide 25 mgNon-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Time to Response by Immunohistochemistry Subtypes2.87 (2.78 to 3.33)2.76 (2.73 to 2.79)
SecondaryPart 2: Time to Response by Gene Expression Profiling Subtypes

Time to response is defined as the time from the starting date of combination therapy to the date objective response criteria were first met. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.

Time frame:
From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Reported as:
Median · months
Part 2: Time to Response by Gene Expression Profiling Subtypes
monthsABC Subtype: Zanubrutinib + Lenalidomide 25 mgGCB Subtype: Zanubrutinib + Lenalidomide 25 mg
Part 2: Time to Response by Gene Expression Profiling Subtypes2.76 (2.73 to 2.83)3.19 (2.79 to 3.48)
SecondaryPart 2: Number of Participants With Treatment-emergent Adverse Events

An AE is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).

Time frame:
From first dose of study drug to 30 days after last dose. Maximum time on treatment in Part 2 was 701 days.
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart 2: Zanubrutinib + Lenalidomide 25 mg
TEAEs39
SAEs14

Adverse events

Collected over All-cause mortality: Up to the end of study, maximum time on study was 41.6 months. AEs: From first dose of study drug to 30 days after last dose. Maximum time on treatment was 1260 days.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Zanubrutinib + Lenalidomide 15 mg3/6 (50%)0/6 (0%)6/6 (100%)
Part 1: Zanubrutinib + Lenalidomide 20 mg5/10 (50%)3/10 (30%)10/10 (100%)
Part 1: Zanubrutinib + Lenalidomide 25 mg3/11 (27.3%)4/11 (36.4%)11/11 (100%)
Part 2: Zanubrutinib + Lenalidomide 25 mg18/39 (46.2%)14/39 (35.9%)39/39 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPart 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mgPart 2: Zanubrutinib + Lenalidomide 25 mg
PneumoniaInfections and infestations0/62/102/114/39
Platelet count decreasedInvestigations0/60/102/112/39
AnaemiaBlood and lymphatic system disorders0/61/101/110/39
Cardiopulmonary failureCardiac disorders0/61/100/110/39
COVID-19Infections and infestations0/61/100/110/39
Neutrophil count decreasedInvestigations0/61/101/112/39
White blood cell count decreasedInvestigations0/61/100/110/39
PyrexiaGeneral disorders0/60/101/110/39
HypokalaemiaMetabolism and nutrition disorders0/60/101/110/39
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/60/101/110/39
Most frequent other events
Showing 10 of 139
Most frequent other events
EventPart 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mgPart 2: Zanubrutinib + Lenalidomide 25 mg
Neutrophil count decreasedInvestigations2/66/1010/1133/39
White blood cell count decreasedInvestigations3/66/1010/1129/39
AnaemiaBlood and lymphatic system disorders2/64/108/1121/39
Platelet count decreasedInvestigations2/67/106/1124/39
Lymphocyte count decreasedInvestigations4/65/106/1114/39
Blood lactate dehydrogenase increasedInvestigations2/66/101/1113/39
HypokalaemiaMetabolism and nutrition disorders2/64/106/1115/39
Weight decreasedInvestigations3/62/101/113/39
CoughRespiratory, thoracic and mediastinal disorders3/61/100/114/39
Alanine aminotransferase increasedInvestigations0/63/105/1110/39

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mgPart 2: Zanubrutinib + Lenalidomide 25 mgTotal
Mean47.8 ± 15.1254.0 ± 14.8358.8 ± 13.1259.1 ± 11.6157.2 ± 12.86
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mgPart 2: Zanubrutinib + Lenalidomide 25 mgTotal
Female2461931
Male4652035
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mgPart 2: Zanubrutinib + Lenalidomide 25 mgTotal
American Indian or Alaska Native00000
Asian610113966
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Part 1: Zanubrutinib + Lenalidomide 15 mgPart 1: Zanubrutinib + Lenalidomide 20 mgPart 1: Zanubrutinib + Lenalidomide 25 mgPart 2: Zanubrutinib + Lenalidomide 25 mgTotal
China610113966
08

Study locations

10 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • Shanghai East Hospital
    Shanghai, Shanghai 200120, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Mar 2024, 42 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 42 months is below that.

Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Jun 17, 2020
StartActual
Sep 11, 2020
Primary completionActual
Mar 28, 2024
CompletionActual
Mar 28, 2024
Results first posted
May 23, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04436107
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Sep 11, 2020
Primary completion
Mar 28, 2024
Completion
Mar 28, 2024
Results posted
May 23, 2025
Last update
May 23, 2025

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Lenalidomide

Start the discussion